Browse > Article
http://dx.doi.org/10.4014/jmb.1605.05020

A Newly Isolated Bacteriophage, PBES 02, Infecting Cronobacter sakazakii  

Lee, Hyung Ju (Hana High School)
Kim, Wan Il (Hana High School)
Kwon, Young Chan (Hana High School)
Cha, Kyung Eun (The Bacteriophage Bank of Korea)
Kim, Minjin (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Myung, Heejoon (The Bacteriophage Bank of Korea)
Publication Information
Journal of Microbiology and Biotechnology / v.26, no.9, 2016 , pp. 1629-1635 More about this Journal
Abstract
A novel bacteriophage, PBES 02, infecting Cronobacter sakazakii was isolated and characterized. It has a spherical head of 90 nm in diameter and a tail of 130 nm in length, and belongs to Myoviridae as observed under a transmission electron microscope. The major virion protein appears to be 38 kilodaltons (kDa) in size. The latent period of PBES 02 is 30 min and the burst size is 250. Infectivity of the phage remained intact after exposure to temperatures ranging from 4℃ to 55℃ for 1 h. It was also stable after exposure to pHs ranging from 6 to 10 for 1 h. The phage effectively removed contaminating Cronobacter sakazakii from broth infant formula. PBES 02 has a double-stranded DNA genome of 149,732 bases. Its GC ratio is 50.7%. Sequence analysis revealed that PBES 02 has 299 open reading frames (ORFs) and 14 tRNA genes. Thirty-nine ORFs were annotated, including 24 related to replication and regulation functions, 10 related to structural proteins, and 5 related to DNA packaging. The genome of PBES 02 is closely related to that of two other C. sakazakii phages, CR3 and CR8. Comparison of DNA sequences of genes encoding the major capsid protein revealed a wide geographical distribution of related phages over Asia, Europe, and America.
Keywords
Bacteriophage PBES 02; Cronobacter sakazakii; genomic analysis; phage therapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Das M, Bhowmick TS, Ahern SJ, Young R, Gonzalez CF. 2015. Control of Pierce's disease by phage. PLoS One 10: e0128902.   DOI
2 Abbasifar R, Griffiths MW, Sabour PM, Ackermann HW, Vandersteegen K, Lavigne R, et al. 2014. Supersize me: Cronobacter sakazakii phage GAP32. Virology 460-461: 138-146.   DOI
3 Abbasifar R, Kropinski AM, Sabour PM, Chambers JR, MacKinnon J, Malig T, Griffiths MW. 2014. Efficiency of bacteriophage therapy against Cronobacter sakazakii in Galleria mellonella (greater wax moth) larvae. Arch. Virol. 159: 2253 - 2261.   DOI
4 Bragg R, van der Westhuizen W, Lee JY, Coetsee E, Boucher C. 2014. Bacteriophages as potential treatment option for antibiotic resistant bacteria. Adv. Exp. Med. Biol. 807: 97-110.
5 Gottesman S, Zipser D. 1978. Deg phenotype of Escherichia coli lon mutants. J. Bacteriol. 133: 844-851.
6 Hatfull GF. 2015. Dark matter of the biosphere: the amazing world of bacteriophage diversity. J. Virol. 89: 8107-8110.   DOI
7 Healy B, Cooney S, O’Brien S, Iversen C, Whyte P, Nally J, et al. 2010. Cronobacter (Enterobacter sakazakii): an opportunistic foodborne pathogen. Foodborne Pathog. Dis. 7: 339-350   DOI
8 Hong SS, Jeong J, Lee J, Kim S, Min W, Myung H. 2013. Therapeutic effects of bacteriophages against Salmonella gallinarum infection in chickens. J. Microbiol. Biotechnol. 23: 1478-1483.   DOI
9 Hunter CJ, Bean JF. 2013. Cronobacter: an emerging opportunistic pathogen associated with neonatal meningitis, sepsis and necrotizing enterocolitis. J. Perinatol. 33: 581-585.   DOI
10 Kim MS, Myung H. 2012. Complete genome of Staphylococcus aureus phage SA11. J. Virol. 86: 10232.   DOI
11 Jackel C, Hammerl JA, Reetz J, Kropinski AM, Hertwig S. 2015. Campylobacter group II phage CP21 is the prototype of a new subgroup revealing a distinct modular genome organization and host specificity. BMC Genomics 16: 629.   DOI
12 Kalyantanda G, Shumyak L, Archibald LK. 2015. Cronobacter species contamination of powdered infant formula and the implications for neonatal health. Front. Pediatr. 3: 56.   DOI
13 Kim KP, Klumpp J, Loessner MJ. 2007. Enterobacter sakazakii bacteriophages can prevent bacterial growth in reconstituted infant formula. Int. J. Food Microbiol. 115: 195-203.   DOI
14 Nobrega FL, Costa AR, Kluskens LD, Azeredo J. 2015. Revisiting phage therapy: new applications for old resources. Trends Microbiol. 23: 185-191.   DOI
15 Kropinski AM, Mazzocco A, Waddell TE, Linghor E, Johnson RP. 2009. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol. Biol. 501: 69-76.
16 Lee YD, Kim JY, Park JH, Chang H. 2012. Genomic analysis of bacteriophage ESP2949-1, which is virulent for Cronobacter sakazakii. Arch. Virol. 157: 199-202.   DOI
17 Manfioletti G, Schneider C. 1988. A new and fast method for preparing high quality lambda DNA suitable for sequencing. Nucleic Acids Res. 16: 2873-2884.   DOI
18 Sambrook J, Russell DW. 2006. Purification of bacteriophage λ particles by centrifugation through a glycerol step gradient. CSH Protoc. 2006: 10.1101/pdb.prot3969.   DOI
19 Shin H, Lee JH, Kim Y, Ryu. S. 2012. Complete genome sequence of Cronobacter sakazakii bacteriophage CR3. J. Virol. 86: 6367-6368.   DOI
20 Yang JA, Kang I, Moon M, Ryu U, Kwon KK, Cho JC, Oh HM. 2016. Complete genome sequence of Celeribacter marinus IMCC12053 (T), the host strain of marine bacteriophage P12053L. Mar. Genomics 26: 5-7.   DOI
21 Singh N, Goel G, Raghav M. 2015. Insights into virulence factors determining the pathogenicity of Cronobacter sakazakii. Virulence 6: 433-440.   DOI
22 Tóthová L, Celec P, Bábíčková J, Gajdošová J, Al-Alami H, Kamodyova N, et al. 2011. Phage therapy of Cronobacter-induced urinary tract infection in mice. Med. Sci. Monit. 17: BR173-BR178.
23 Viertel TM, Ritter K, Horz HP. 2014. Viruses versus bacteria - novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J. Antimicrob. Chemother. 69: 2326-2336.   DOI
24 Zuber S, Boissin-Delaporte C, Michot L, Iversen C, Diep B, Brüssow H, Breeuwer P. 2008. Decreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problems. Microb. Biotechnol. 1: 532-543.   DOI